tirzepatide for heart failure with preserved ejection fraction and obesity Another "Positive" Trial that Falls Short Association of Tirzepatide Use With

A recent study from Johns Hopkins School of Medicine shows that a molecule called NLY01, which can cross the blood-brain barrier, BBB, and enter the brain, is helpful in protecting nerve cells in mouse models of Parkinson's disease

Urgent medical assessment is required for severe abdominal pain (possible pancreatitis), anaphylaxis, persistent vomiting, or signs of dehydration whilst taking Mounjaro

Talk to your prescriber before changing how you dose

doi: 10.7759/cureus.34640

Synthroid helps people with thyroid problems live healthier lives by restoring normal thyroid function

Phase 2 trial results (48 weeks, adults with obesity): 1 mg dose: 7.2% body weight loss 4 mg dose: 12.9% body weight loss 8 mg dose: 17.3% body weight loss 12 mg dose: 24.2% body weight loss Placebo: 1.6% body weight loss Phase 3 TRIUMPH-4 results: 9 mg dose: 20.0% body weight loss (22.9 kg / 50.5 lbs) 12 mg dose: 23.7% body weight loss (27.2 kg / 60.0 lbs) Placebo: 4.6% body weight loss In a separate phase 3 analysis, retatrutide at the highest dose achieved up to 28.7% weight loss